HC Wainwright & Co. Reiterates Buy on Pasithea Therapeutics, Maintains $3 Price Target
Benzinga Newsdesk 4 months ago
NewsPrice TargetReiterationAnalyst Ratings
HC Wainwright & Co. analyst Sara Nik reiterates Pasithea Therapeutics (NASDAQ:KTTA) with a Buy and maintains $3 price target.
HC Wainwright & Co. analyst Sara Nik reiterates Pasithea Therapeutics (NASDAQ:KTTA) with a Buy and maintains $3 price target.